Finally we analyzed OS (measured from diagnosis), OS-Ph1 (measured from recorded phase I therapy), and DMFS (measured from diagnosis to metastatic disease) for patients with PIK3CA mutations and wt PIK3CA patients (Table 3). Here, PIK3CA is linked to metastatic neoplasm.